Palvella Therapeutics (PVLA)
142.18
-1.76 (1.22%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)
July 22, 2026 6:52 AM - StreetInsider
Form 4 PALVELLA THERAPEUTICS, For: Jul 15 Filed by: Goin Kathleen
July 17, 2026 4:05 PM - SEC Filing
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
July 15, 2026 4:20 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: Jul 14
July 14, 2026 4:49 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 29 Filed by: Pauls Matthew
July 1, 2026 4:06 PM - SEC Filing
Form 3 PALVELLA THERAPEUTICS, For: Jun 29 Filed by: Pauls Matthew
July 1, 2026 4:05 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: Jun 29
June 30, 2026 7:37 AM - SEC Filing
Palvella Therapeutics adds Matt Pauls to its board of directors
June 30, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
June 30, 2026 7:30 AM - Globe NewsWire
Palvella files first NDA module for rare lymphatic malformation drug
June 29, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
June 29, 2026 7:30 AM - Globe NewsWire
Canaccord Reiterates Buy Rating on Palvella Therapeutics (PVLA)
June 25, 2026 6:41 AM - StreetInsider
Form 4 PALVELLA THERAPEUTICS, For: Jun 17 Filed by: Goin Kathleen
June 22, 2026 5:06 PM - SEC Filing
FDA grants rolling review for Palvella's rapamycin NDA for rare condition
June 22, 2026 7:30 AM - StreetInsider
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
June 22, 2026 7:30 AM - Globe NewsWire
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
June 17, 2026 5:12 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 12 Filed by: Korenberg Matthew E
June 16, 2026 4:07 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: Jun 10
June 16, 2026 8:31 AM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: KIRITSY CHRISTOPHER P
June 12, 2026 4:08 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: JENKINS GEORGE M
June 12, 2026 4:08 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: HERON ELAINE J
June 12, 2026 4:07 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: Doux John
June 12, 2026 4:07 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: Davis Todd C
June 12, 2026 4:07 PM - SEC Filing
Form 4 PALVELLA THERAPEUTICS, For: Jun 10 Filed by: Wessel Tadd S.
June 12, 2026 4:06 PM - SEC Filing
ResVita Bio adds dermatologist John Doux to board of directors
June 9, 2026 8:43 AM - StreetInsider
ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors
June 9, 2026 8:43 AM - PR NewsWire
Palvella Therapeutics completes FDA pre-NDA meeting for QTORIN rapamycin
June 3, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
June 3, 2026 7:30 AM - Globe NewsWire
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 2, 2026 7:30 AM - Globe NewsWire
Palvella Therapeutics receives Yale-licensed patent for QTORIN pitavastatin
May 27, 2026 7:31 AM - StreetInsider
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
May 27, 2026 7:30 AM - Globe NewsWire
Form 4 PALVELLA THERAPEUTICS, For: May 20 Filed by: Goin Kathleen
May 22, 2026 4:06 PM - SEC Filing
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
May 21, 2026 7:30 AM - Globe NewsWire
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
May 20, 2026 5:48 PM - SEC Filing
Form 8-K PALVELLA THERAPEUTICS, For: May 20
May 20, 2026 4:35 PM - SEC Filing
Palvella presents positive data for QTORIN rapamycin at vascular congress
May 20, 2026 4:30 PM - StreetInsider
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Dise
May 20, 2026 4:30 PM - Globe NewsWire
Form 8-K PALVELLA THERAPEUTICS, For: May 15
May 15, 2026 7:30 AM - SEC Filing
Palvella reports positive bleeding results from QTORIN rapamycin trial
May 15, 2026 7:30 AM - StreetInsider
Palvella reports positive bleeding results from rapamycin trial
May 15, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Der
May 15, 2026 7:30 AM - Globe NewsWire
Palvella Therapeutics moves to NASDAQ Global Market
May 13, 2026 7:30 AM - StreetInsider
Form 8-K PALVELLA THERAPEUTICS, For: May 11
May 13, 2026 7:30 AM - SEC Filing
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
May 13, 2026 7:30 AM - Globe NewsWire
Stephens Starts Palvella Therapeutics (PVLA) at Overweight
May 12, 2026 2:54 AM - StreetInsider
Palvella Therapeutics (PVLA) PT Lowered to $240 at Mizuho
May 11, 2026 6:43 AM - StreetInsider
Form 8-K PALVELLA THERAPEUTICS, For: May 07
May 7, 2026 9:10 AM - SEC Filing
Form 10-Q PALVELLA THERAPEUTICS, For: Mar 31
May 7, 2026 8:31 AM - SEC Filing
Palvella Therapeutics (PVLA) Misses Q1 EPS by 120c
May 7, 2026 8:10 AM - StreetInsider
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 7, 2026 7:30 AM - Globe NewsWire
Oppenheimer Assumes Palvella Therapeutics (PVLA) at Outperform
May 4, 2026 8:16 AM - StreetInsider
Palvella Therapeutics begins Phase 2 trial for rare skin condition
May 4, 2026 7:30 AM - StreetInsider
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
May 4, 2026 7:30 AM - Globe NewsWire
Form ARS PALVELLA THERAPEUTICS, For: Dec 31
April 30, 2026 4:20 PM - SEC Filing
Form DEFA14A PALVELLA THERAPEUTICS,
April 30, 2026 4:18 PM - SEC Filing
Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10
April 30, 2026 4:09 PM - SEC Filing
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
April 30, 2026 7:30 AM - Globe NewsWire
Full Article List
